<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36889799</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Risk of COVID-19 among unvaccinated and vaccinated patients with systemic lupus erythematosus: a general population study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e002839</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2022-002839</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To compare the risk of SARS-CoV-2 infection and its related severe sequelae between patients with systemic lupus erythematosus (SLE) and the general population according to COVID-19 vaccination status.</AbstractText><AbstractText Label="METHODS">We performed cohort studies using data from The Health Improvement Network to compare the risks of SARS-CoV-2 infection and severe sequelae between patients with SLE and the general population. Individuals aged 18-90 years with no previously documented SARS-CoV-2 infection were included. We estimated the incidence rates and HRs of SARS-CoV-2 infection and severe sequelae between patients with SLE and the general population according to COVID-19 vaccination status using exposure score overlap weighted Cox proportional hazards model.</AbstractText><AbstractText Label="RESULTS">We identified 3245 patients with SLE and 1&#x2009;755&#x2009;034 non-SLE individuals from the unvaccinated cohort. The rates of SARS-CoV-2 infection, COVID-19 hospitalisation, COVID-19 death and combined severe outcomes per 1000 person-months were 10.95, 3.21, 1.16 and 3.86 among patients with SLE, and 8.50, 1.77, 0.53 and 2.18 among general population, respectively. The corresponding adjusted HRs were 1.28 (95% CI: 1.03 to 1.59), 1.82 (95% CI: 1.21 to 2.74), 2.16 (95% CI: 1.00 to 4.79) and 1.78 (95% CI: 1.21 to 2.61). However, no statistically significant differences were observed between vaccinated patients with SLE and vaccinated general population over 9&#x2009;months of follow-up.</AbstractText><AbstractText Label="CONCLUSION">While unvaccinated patients with SLE were at higher risk of SARS-CoV-2 infection and its severe sequelae than the general population, no such difference was observed among vaccinated population. The findings indicate that COVID-19 vaccination provides an adequate protection to most patients with SLE from COVID-19 breakthrough infection and its severe sequelae.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sparks</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5556-4618</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Xinjia</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Arthritis Research Canada, Richmond, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Dongxing</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yilun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Key Laboratory of Joint Degeneration and Injury, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Guanghua</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hunan Key Laboratory of Joint Degeneration and Injury, Changsha, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Jie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3510-8241</Identifier><AffiliationInfo><Affiliation>Health Management Center, Xiangya Hospital, Central South University, Changsha, China weij1988@csu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yuqing</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-7638-0888</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000718127">COVID-19 breakthrough infections</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="N">vaccination</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>20</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36889799</ArticleId><ArticleId IdType="pmc">PMC10008206</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2022-002839</ArticleId><ArticleId IdType="pii">rmdopen-2022-002839</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
COVID-19 weekly epidemiological update. 2022. Available: covid19.who.int [Accessed 2 Nov 2022].</Citation></Reference><Reference><Citation>Dye C. The benefits of large scale covid-19 vaccination. BMJ 2022;377:867. 10.1136/bmj.o867</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o867</ArticleId><ArticleId IdType="pubmed">35477535</ArticleId></ArticleIdList></Reference><Reference><Citation>Creech CB, Walker SC, Samuels RJ. SARS-cov-2 vaccines. JAMA 2021;325:1318&#x2013;20. 10.1001/jama.2021.3199</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3199</ArticleId><ArticleId IdType="pubmed">33635317</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq S, Van Eeden C, Tervaert JWC, et al. . COVID-19, rheumatic diseases and immune dysregulation-a perspective. Clin Rheumatol 2021;40:433&#x2013;42. 10.1007/s10067-020-05529-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-020-05529-y</ArticleId><ArticleId IdType="pmc">PMC7788381</ArticleId><ArticleId IdType="pubmed">33411143</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Ruiz R, Paredes JL, Niewold TB. COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. Transl Res 2021;232:13&#x2013;36.:S1931-5244(20)30302-9. 10.1016/j.trsl.2020.12.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2020.12.007</ArticleId><ArticleId IdType="pmc">PMC7749645</ArticleId><ArticleId IdType="pubmed">33352298</ArticleId></ArticleIdList></Reference><Reference><Citation>Park Y-W, Kee S-J, Cho Y-N, et al. . Impaired differentiation and cytotoxicity of natural killer cells in systemic lupus erythematosus. Arthritis Rheum 2009;60:1753&#x2013;63. 10.1002/art.24556</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24556</ArticleId><ArticleId IdType="pubmed">19479851</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques CDL, Kakehasi AM, Pinheiro MM, et al. . High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of reumacov brasil registry. RMD Open 2021;7:e001461. 10.1136/rmdopen-2020-001461</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2020-001461</ArticleId><ArticleId IdType="pmc">PMC7844930</ArticleId><ArticleId IdType="pubmed">33510041</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawalha AH, Zhao M, Coit P, et al. . Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients. Clin Immunol 2020;215:108410.:S1521-6616(20)30239-4. 10.1016/j.clim.2020.108410</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108410</ArticleId><ArticleId IdType="pmc">PMC7139239</ArticleId><ArticleId IdType="pubmed">32276140</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med 2020;172:ITC81&#x2013;96. 10.7326/AITC202006020</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/AITC202006020</ArticleId><ArticleId IdType="pubmed">32479157</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees F, Doherty M, Grainge M, et al. . Burden of comorbidity in systemic lupus erythematosus in the UK, 1999-2012. Arthritis Care Res (Hoboken) 2016;68:819&#x2013;27. 10.1002/acr.22751</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22751</ArticleId><ArticleId IdType="pubmed">26473719</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Alarc&#xf3;n GS, Izadi Z, et al. . Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 global rheumatology alliance. Ann Rheum Dis 2022;81:970&#x2013;8.:annrheumdis-2021-221636. 10.1136/annrheumdis-2021-221636</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221636</ArticleId><ArticleId IdType="pmc">PMC8882632</ArticleId><ArticleId IdType="pubmed">35172961</ArticleId></ArticleIdList></Reference><Reference><Citation>Gartshteyn Y, Askanase AD, Schmidt NM, et al. . COVID-19 and systemic lupus erythematosus: a case series. Lancet Rheumatol 2020;2:e452&#x2013;4. 10.1016/S2665-9913(20)30161-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30161-2</ArticleId><ArticleId IdType="pmc">PMC7250558</ArticleId><ArticleId IdType="pubmed">32835249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozzalla Cassione E, Zanframundo G, Biglia A, et al. . COVID-19 infection in a northern-italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis 2020;79:1382&#x2013;3. 10.1136/annrheumdis-2020-217717</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217717</ArticleId><ArticleId IdType="pubmed">32398281</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez GA, Gerosa M, Beretta L, et al. . COVID-19 in systemic lupus erythematosus: data from a survey on 417 patients. Semin Arthritis Rheum 2020;50:1150&#x2013;7.:S0049-0172(20)30194-3. 10.1016/j.semarthrit.2020.06.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2020.06.012</ArticleId><ArticleId IdType="pmc">PMC7836639</ArticleId><ArticleId IdType="pubmed">32927376</ArticleId></ArticleIdList></Reference><Reference><Citation>Favalli EG, Gerosa M, Murgo A, et al. . Are patients with systemic lupus erythematosus at increased risk for COVID-19? Ann Rheum Dis 2021;80:e25. 10.1136/annrheumdis-2020-217787</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217787</ArticleId><ArticleId IdType="pubmed">32451344</ArticleId></ArticleIdList></Reference><Reference><Citation>Goyal M, Patil P, Pathak H, et al. . Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India. Ann Rheum Dis 2021;80:e71. 10.1136/annrheumdis-2020-218013</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218013</ArticleId><ArticleId IdType="pubmed">32669305</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageau A, Aldebert G, Van Gysel D, et al. . SARS-cov-2 infection among inpatients with systemic lupus erythematosus in France: a nationwide epidemiological study. Ann Rheum Dis 2021;80:1101&#x2013;2. 10.1136/annrheumdis-2021-220010</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220010</ArticleId><ArticleId IdType="pubmed">33727216</ArticleId></ArticleIdList></Reference><Reference><Citation>Schioppo T, Argolini LM, Sciascia S, et al. . Clinical and peculiar immunological manifestations of SARS-cov-2 infection in systemic lupus erythematosus patients. Rheumatology (Oxford) 2022;61:1928&#x2013;35.:keab611. 10.1093/rheumatology/keab611</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab611</ArticleId><ArticleId IdType="pmc">PMC8385869</ArticleId><ArticleId IdType="pubmed">34352079</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageau A, Papo T, Ruckly S, et al. . Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in France: a nationwide study. Ann Rheum Dis 2022;81:569&#x2013;74.:annrheumdis-2021-221599. 10.1136/annrheumdis-2021-221599</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221599</ArticleId><ArticleId IdType="pubmed">34893471</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordtz R, Kristensen S, Dalgaard LPH, et al. . Incidence of COVID-19 hospitalisation in patients with systemic lupus erythematosus: a nationwide cohort study from Denmark. J Clin Med 2021;10:17.:3842. 10.3390/jcm10173842</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10173842</ArticleId><ArticleId IdType="pmc">PMC8432052</ArticleId><ArticleId IdType="pubmed">34501290</ArticleId></ArticleIdList></Reference><Reference><Citation>Raiker R, Pakhchanian H, DeYoung C, et al. . Short term outcomes of COVID-19 in lupus: propensity score matched analysis from a nationwide multi-centric research network. J Autoimmun 2021;125:102730.:S0896-8411(21)00138-4. 10.1016/j.jaut.2021.102730</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102730</ArticleId><ArticleId IdType="pmc">PMC8501265</ArticleId><ArticleId IdType="pubmed">34649723</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoglio IM, Valim JM de L, Daffre D, et al. . Poor prognosis of COVID-19 acute respiratory distress syndrome in lupus erythematosus: nationwide cross-sectional population study of 252 119 patients. ACR Open Rheumatol 2021;3:804&#x2013;11. 10.1002/acr2.11329</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11329</ArticleId><ArticleId IdType="pmc">PMC8593786</ArticleId><ArticleId IdType="pubmed">34423922</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena A, Engel AJ, Banbury B, et al. . Breakthrough SARS-cov-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City. Lancet Rheumatol 2022;4:e582&#x2013;5. 10.1016/S2665-9913(22)00190-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(22)00190-4</ArticleId><ArticleId IdType="pmc">PMC9275793</ArticleId><ArticleId IdType="pubmed">35856060</ArticleId></ArticleIdList></Reference><Reference><Citation>Izmirly PM, Kim MY, Samanovic M, et al. . Evaluation of immune response and disease status in systemic lupus erythematosus patients following SARS-cov-2 vaccination. Arthritis Rheumatol 2022;74:284&#x2013;94. 10.1002/art.41937</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41937</ArticleId><ArticleId IdType="pmc">PMC8426963</ArticleId><ArticleId IdType="pubmed">34347939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammitzb&#xf8;ll C, Bartels LE, B&#xf8;gh Andersen J, et al. . Impaired antibody response to the bnt162b2 messenger RNA coronavirus disease 2019 vaccine in patients with systemic lupus erythematosus and rheumatoid arthritis. ACR Open Rheumatol 2021;3:622&#x2013;8. 10.1002/acr2.11299</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11299</ArticleId><ArticleId IdType="pmc">PMC8426741</ArticleId><ArticleId IdType="pubmed">34273260</ArticleId></ArticleIdList></Reference><Reference><Citation>Mageau A, Ferr&#xe9; VM, Goulenok T, et al. . Severely impaired humoral response against SARS-cov-2 variants of concern following two doses of bnt162b2 vaccine in patients with systemic lupus erythematosus (SLE). Ann Rheum Dis 2022;81:1194&#x2013;6. 10.1136/annrheumdis-2022-222498</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-222498</ArticleId><ArticleId IdType="pubmed">35396228</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyon Q, Sterlin D, Miyara M, et al. . BNT162b2 vaccine-induced humoral and cellular responses against SARS-cov-2 variants in systemic lupus erythematosus. Ann Rheum Dis 2022;81:575&#x2013;83. 10.1136/annrheumdis-2021-221097</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221097</ArticleId><ArticleId IdType="pmc">PMC8494536</ArticleId><ArticleId IdType="pubmed">34607791</ArticleId></ArticleIdList></Reference><Reference><Citation>Vezyridis P, Timmons S. Evolution of primary care databases in UK: a scientometric analysis of research output. BMJ Open 2016;6:e012785. 10.1136/bmjopen-2016-012785</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-012785</ArticleId><ArticleId IdType="pmc">PMC5073525</ArticleId><ArticleId IdType="pubmed">27729352</ArticleId></ArticleIdList></Reference><Reference><Citation>Petherick ES, Pickett KE, Cullum NA. Can different primary care databases produce comparable estimates of burden of disease: results of a study exploring venous leg ulceration. Fam Pract 2015;32:374&#x2013;80. 10.1093/fampra/cmv013</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmv013</ArticleId><ArticleId IdType="pmc">PMC5942540</ArticleId><ArticleId IdType="pubmed">25934977</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis JD, Schinnar R, Bilker WB, et al. . Validation studies of the health improvement network (thin) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007;16:393&#x2013;401. 10.1002/pds.1335</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.1335</ArticleId><ArticleId IdType="pubmed">17066486</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Thomas SL, Schoonen WM, et al. . Validation and validity of diagnoses in the general practice research database: a systematic review. Br J Clin Pharmacol 2010;69:4&#x2013;14. 10.1111/j.1365-2125.2009.03537.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.2009.03537.x</ArticleId><ArticleId IdType="pmc">PMC2805870</ArticleId><ArticleId IdType="pubmed">20078607</ArticleId></ArticleIdList></Reference><Reference><Citation>Blak BT, Thompson M, Dattani H, et al. . Generalisability of the health improvement network (thin) database: demographics, chronic disease prevalence and mortality rates. Inform Prim Care 2011;19:251&#x2013;5. 10.14236/jhi.v19i4.820</Citation><ArticleIdList><ArticleId IdType="doi">10.14236/jhi.v19i4.820</ArticleId><ArticleId IdType="pubmed">22828580</ArticleId></ArticleIdList></Reference><Reference><Citation>Chisholm J. The read clinical classification. BMJ 1990;300:1092. 10.1136/bmj.300.6732.1092</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.300.6732.1092</ArticleId><ArticleId IdType="pmc">PMC1662793</ArticleId><ArticleId IdType="pubmed">2344534</ArticleId></ArticleIdList></Reference><Reference><Citation>
Databank F. n.d.
FDB multilex. Available: www.fdbhealth.co.uk/solutions/multilex-clinicaldecision-support
</Citation></Reference><Reference><Citation>Xie D, Choi HK, Dalbeth N, et al. . Gout and excess risk of severe SARS-cov-2 infection among vaccinated individuals: a general population study. Arthritis Rheumatol 2023;75:122&#x2013;32. 10.1002/art.42339</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42339</ArticleId><ArticleId IdType="pmc">PMC9537980</ArticleId><ArticleId IdType="pubmed">36082457</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wallace ZS, Sparks JA, et al. . Risk of COVID-19 among unvaccinated and vaccinated patients with rheumatoid arthritis: a general population study. Arthritis Care Res (Hoboken) 26, 2022. 10.1002/acr.25028</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.25028</ArticleId><ArticleId IdType="pmc">PMC9538842</ArticleId><ArticleId IdType="pubmed">36161711</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees F, Doherty M, Grainge M, et al. . The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012. Ann Rheum Dis 2016;75:136&#x2013;41. 10.1136/annrheumdis-2014-206334</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206334</ArticleId><ArticleId IdType="pmc">PMC4717400</ArticleId><ArticleId IdType="pubmed">25265938</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts RA, Al-Taiar A, Scott DGI, et al. . Prevalence and incidence of Wegener&#x2019;s granulomatosis in the UK general practice research database. Arthritis Rheum 2009;61:1412&#x2013;6. 10.1002/art.24544</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24544</ArticleId><ArticleId IdType="pubmed">19790134</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandan JS, Zemedikun DT, Thayakaran R, et al. . Nonsteroidal antiinflammatory drugs and susceptibility to COVID-19. Arthritis Rheumatol 2021;73:731&#x2013;9. 10.1002/art.41593</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41593</ArticleId><ArticleId IdType="pmc">PMC8252419</ArticleId><ArticleId IdType="pubmed">33185016</ArticleId></ArticleIdList></Reference><Reference><Citation>Meropol SB, Metlay JP. Accuracy of pneumonia hospital admissions in a primary care electronic medical record database. Pharmacoepidemiol Drug Saf 2012;21:659&#x2013;65. 10.1002/pds.3207</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3207</ArticleId><ArticleId IdType="pmc">PMC3371176</ArticleId><ArticleId IdType="pubmed">22374684</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Thomas LE, Li F. Addressing extreme propensity scores via the overlap weights. Am J Epidemiol 2019;188:250&#x2013;7. 10.1093/aje/kwy201</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwy201</ArticleId><ArticleId IdType="pubmed">30189042</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA 2020;323:2417&#x2013;8. 10.1001/jama.2020.7819</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.7819</ArticleId><ArticleId IdType="pubmed">32369102</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083&#x2013;107. 10.1002/sim.3697</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3697</ArticleId><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 1999;94:496&#x2013;509. 10.1080/01621459.1999.10474144</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1999.10474144</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkler D, Ploner M, Schemper M, et al. . Weighted cox regression using the R package coxphw. J Stat Softw 2018;84:1&#x2013;26. 10.18637/jss.v084.i02</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v084.i02</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergnes JN. Safety and efficacy of the bnt162b2 mRNA covid-19 vaccine. N Engl J Med 2021;384:1576&#x2013;8. 10.1056/NEJMc2036242</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2036242</ArticleId><ArticleId IdType="pubmed">33596348</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden LR, El Sahly HM, Essink B, et al. . Efficacy and safety of the mrna-1273 SARS-cov-2 vaccine. N Engl J Med 2021;384:403&#x2013;16.:NEJMoa2035389. 10.1056/NEJMoa2035389</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Qin C, Liu M, et al. . Effectiveness and safety of SARS-cov-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty 2021;10:132. 10.1186/s40249-021-00915-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-021-00915-3</ArticleId><ArticleId IdType="pmc">PMC8590867</ArticleId><ArticleId IdType="pubmed">34776011</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M, Clemens SAC, Madhi SA, et al. . Safety and efficacy of the chadox1 ncov-19 vaccine (AZD1222) against SARS-cov-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99&#x2013;111.:S0140-6736(20)32661-1. 10.1016/S0140-6736(20)32661-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>